These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1473872)

  • 1. Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size.
    Steinijans VW; Hauck WW; Diletti E; Hauschke D; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 Dec; 30(12):571-5. PubMed ID: 1473872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reference tables for the intrasubject coefficient of variation in bioequivalence studies.
    Steinijans VW; Sauter R; Hauschke D; Diletti E; Schall R; Luus HG; Elze M; Blume H; Hoffmann C; Franke G
    Int J Clin Pharmacol Ther; 1995 Aug; 33(8):427-30. PubMed ID: 8556220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies.
    Hauschke D; Steinijans WV; Diletti E; Schall R; Luus HG; Elze M; Blume H
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):376-8. PubMed ID: 7952801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations.
    Agrawal S; Kaur KJ; Singh I; Bhade S; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Nov; 9(11):1273-80. PubMed ID: 16333937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation of Cmax and Cmax/AUC in investigations of bioequivalence.
    Endrenyi L; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1993 Apr; 31(4):184-9. PubMed ID: 8500920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Average bioequivalence of two oral formulations of fluconazole in healthy subjects after multiple dosing.
    Atanasova I; Bozhinova K; Terziivanov D
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):282-5. PubMed ID: 10395119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability of two tablet formulations of ibuprofen.
    el-Sayed YM; Gouda MW; al-Khamis KI; al-Meshal MA; al-Dhawailie AA; al-Rayes S; Bin-Salih SA; al-Rashood KA
    Int J Clin Pharmacol Ther; 1995 May; 33(5):294-8. PubMed ID: 7655769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.